

GLAXOSMITHKLINE PLC  
Form 6-K  
July 14, 2008

**FORM 6-K**

**SECURITIES AND EXCHANGE COMMISSION**  
**Washington D.C. 20549**

**Report of Foreign Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

For period ending July 14, 2008

**GlaxoSmithKline plc**  
(Name of registrant)

**980 Great West Road, Brentford, Middlesex, TW8 9GS**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

--

**Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or  
Connected Persons**

I give below details of an increase in interests in the Ordinary shares of GlaxoSmithKline plc in respect of the personal holdings of the under-mentioned persons at a price of £12.44 per Ordinary share, following the re-investment of the dividend paid to shareholders on 10 July 2008.

|                |     |
|----------------|-----|
| Mr A P Witty   | 25  |
| Mrs C M Witty  | 334 |
| Mr J S Heslop  | 337 |
| Mrs P A Heslop | 81  |
| Mr D Learmouth | 78  |
| Dr D Pulman    | 151 |
| Mrs C R Pulman | 50  |

The Company and the above named persons were advised of this information on 11 July 2008.

This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

S M Bicknell

Company Secretary

14 July 2008

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

**GlaxoSmithKline plc**  
(Registrant)

Date: July 14, 2008

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc